KZA — Kazia Therapeutics Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$18.24m
- AU$14.80m
- AU$0.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.58 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 808.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -101.06% | ||
| Return on Equity | -134.97% | ||
| Operating Margin | -91918.57% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.1 | 0.07 | 15.22 | 0 | 0.02 | 22.06 | 22.06 | -28.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +27.27 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kazia Therapeutics Limited is an Australia-based oncology-focused biotechnology company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.
Directors
- Iain Ross NEC
- James Garner CEO (43)
- John Friend OTH (51)
- Lilischkis Kimberley OTH
- Peng Leong OTH
- Stephen Palmer OTH
- Justine Stehn OTH
- Kate Hill SEC
- Bryce Carmine NED
- Steven Coffey NED
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- March 18th, 1994
- Public Since
- September 1st, 1994
- No. of Shareholders
- 3,204
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 228,029,114
- Address
- Three International Towers Level 24, SYDNEY, 2000
- Web
- https://www.kaziatherapeutics.com/
- Phone
- +61 294724100
- Auditors
- BDO Australia Ltd
Upcoming Events for KZA
Kazia Therapeutics Ltd Annual Shareholders Meeting
Half Year 2024 Kazia Therapeutics Ltd Earnings Release
Similar to KZA
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Kazia Therapeutics share price?
As of Today at 06:12 UTC, shares in Kazia Therapeutics are trading at AU$0.08. This share price information is delayed by 15 minutes.
How has the Kazia Therapeutics share price performed this year?
Shares in Kazia Therapeutics last closed at AU$0.08 and the price had moved by -19.19% over the past 365 days. In terms of relative price strength the Kazia Therapeutics share price has underperformed the ASX All Ordinaries Index by -18.42% over the past year.
What are the analyst and broker recommendations for Kazia Therapeutics?
The overall consensus recommendation for Kazia Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kazia Therapeutics dividend yield?
Kazia Therapeutics does not currently pay a dividend.
Does Kazia Therapeutics pay a dividend?
Kazia Therapeutics does not currently pay a dividend.
When does Kazia Therapeutics next pay dividends?
Kazia Therapeutics does not currently pay a dividend.
How do I buy Kazia Therapeutics shares?
To buy shares in Kazia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kazia Therapeutics?
As of the previous close price of AU$0.08, shares in Kazia Therapeutics had a market capitalisation of AU$18.24m.
Where are Kazia Therapeutics shares listed?
Here are the trading details for Kazia Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: KZA
What kind of share is Kazia Therapeutics?
Based on an overall assessment of its quality, value and momentum Kazia Therapeutics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kazia Therapeutics share price forecast for 2023?
The analyst consensus target price for shares in Kazia Therapeutics is AU$0.30. That is 275% above the last closing price of AU$0.08.
Analysts covering Kazia Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of AU$0.01 for the next financial year.
Find out moreWhat is the trend in the Kazia Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kazia Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -53.15%.
As of the last closing price of AU$0.08, shares in Kazia Therapeutics were trading -45.63% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kazia Therapeutics PE Ratio?
The Kazia Therapeutics PE ratio based on its reported earnings over the past 12 months is 6.58. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kazia Therapeutics?
Kazia Therapeutics' management team is headed by:
- Iain Ross - NEC
- James Garner - CEO
- John Friend - OTH
- Lilischkis Kimberley - OTH
- Peng Leong - OTH
- Stephen Palmer - OTH
- Justine Stehn - OTH
- Kate Hill - SEC
- Bryce Carmine - NED
- Steven Coffey - NED